News
-
-
PRESS RELEASE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-
-
-
PRESS RELEASE
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza publishes restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients as discontinued operations. Restatement includes updated income statement and key performance measures -
-
-
-
PRESS RELEASE
Aosom France x FFHandball: Enhancing the Fan Experience Through Home & Outdoor Living Solutions
Aosom partners with FFHandball, the official governing body for handball in France, to enhance fan experience with innovative home and outdoor living solutions, combining sport with daily life